Welcome to our dedicated page for THERMO FISHER SCIENTIFIC SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
Thermo Fisher Scientific executive Lisa P. Britt, Sr. VP and Chief HR Officer, exercised stock options for 5850.0000 shares of common stock at an exercise price of $309.6300 per share on August 6, 2026, then sold 5850.0000 shares at $580.0000 per share the same day. The option, covering 5850.0000 shares and originally expiring on 2027-02-25, had vested in four equal installments from 2021 through 2024 and is now fully exercised with no remaining derivative position.
Thermo Fisher Scientific Chairman & CEO Marc N. Casper exercised stock options for 10,000 shares of common stock at an exercise price of $309.63 per share on August 6, 2026, then, under a Rule 10b5-1 trading plan adopted April 27, 2026, sold an aggregate 15,000 common shares in multiple transactions at weighted-average prices generally between the low $570s and high $570s, both directly and indirectly through Floral Park Associates, Inc. The exercised option, which vested in four equal installments from 2021–2024, expires on February 25, 2027, and 20,550 options remain outstanding afterward.
Thermo Fisher Scientific Chairman & CEO Marc N. Casper exercised 10,000 stock options at $309.63 per share on August 5, 2026, acquiring an equal number of common shares, and then, together with an affiliated entity, sold 15,000 shares at weighted‑average prices between $565.86 and $577.63 under a Rule 10b5‑1 trading plan adopted April 27, 2026. The exercised option grant now shows 30,550 options remaining, expiring February 25, 2027.
TMO reports a planned sale of 4,883 shares of common stock through Fidelity Brokerage Services on the NYSE on 08/07/2026, with an aggregate market value of $2,822,374.00. These shares consist of 4,608 from restricted stock vesting dated 02/15/2013 and 275 from a stock option exercise on 08/07/2026. The issuer reports 369,747,286 common shares outstanding. In the prior three months, entities including Floral Park Associates Inc. and Marc N. Casper completed multiple common stock sales ranging from 5,000 to 10,000 shares per transaction.
Thermo Fisher Scientific’s affiliate filed to permit the public resale of 15,000 shares of common stock on the NYSE, with an aggregate market value of $8,652,000.00 and 369,747,286 common shares outstanding as of August 6, 2026.
The shares derive from a planned 10,000-share stock option exercise on August 6, 2026 and 5,000 shares from restricted stock vesting events in 2013 and 2015. Over the prior three months, Floral Park Associates Inc. sold 5,000 shares for $2,876,145.43 and Marc N. Casper sold 10,000 shares for $5,752,296.00.
An affiliate of the issuer with symbol TMO has notified an intention to sell up to 15,000 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $8,518,950.00 as of 08/05/2026.
The shares derive from 5,000 shares acquired via restricted stock vesting on 02/26/2015 as compensation and 10,000 shares to be acquired through a stock option exercise for cash on 08/05/2026. The issuer reports 369,747,286 common shares outstanding, which is a baseline figure, not the amount being sold.
Thermo Fisher Scientific Inc. reported Q2 2026 revenue of $11,994 million, up 10% year over year (5% organic). GAAP operating income rose to $2,087 million with a 17.4% margin, while adjusted operating income reached $2,735 million with a 22.8% margin. GAAP diluted EPS was $4.68, up 9%, and adjusted EPS $6.03, up 13%.
Growth was broad-based: Laboratory Products and Biopharma Services revenue increased 12%, Life Sciences Solutions 13%, Analytical Instruments 7% and Specialty Diagnostics 6%, all with margin expansion supported by productivity initiatives. Remaining performance obligations totaled $29.70 billion, about 52% expected to convert to revenue within 12 months.
For the first six months of 2026, cash from operations was $3,317 million and free cash flow $2,503 million. The company used $8,872 million on acquisitions, mainly the $9,098 million Clario Holdings purchase, and $4,000 million on share repurchases, reducing cash to $4,064 million and increasing total debt to $42,549 million. It agreed to sell its microbiology business for approximately $1.075 billion and recorded $147 million of restructuring and other costs year to date, with additional charges of about $220 million expected, primarily in 2026.
Thermo Fisher Scientific Inc. President & COO Gianluca Pettiti sold 400 shares of Common Stock on July 27, 2026 at $565.00 per share in an open-market or private transaction. The sale was effected under a Rule 10b5-1 trading plan adopted on September 12, 2025, and left him with 24,650.832 directly owned shares.